Setback in Europe Clouds Growth Outlook for Acadia

Acadia Pharmaceuticals has encountered a significant obstacle for its European expansion strategy. Market uncertainty followed the announcement of a negative trend vote from the European Medicines Agency’s (EMA) committee regarding the approval of trofinetide for Rett syndrome. This development raises questions about whether the company’s robust U.S. commercial performance can offset this international regulatory delay.

The company’s plans received a blow following a vote by the EMA’s Committee for Medicinal Products for Human Use (CHMP). While a final, formal decision is still pending, the current negative trend indicates that trofinetide is unlikely to secure EU marketing authorization on its first attempt. Investors reacted swiftly, putting Read more...